Scientific article

Traitement combiné d'insuline et d'analogue du GLP-1 : qu'en attendre ?

Published inRevue médicale suisse, vol. 10, no. 433, p. 1235-1240
Publication date2014

Type 2 diabetes mellitus is a progressive and heterogeneous disease. The decrease in insulin secretion by pancreatic beta cells and the increase of glucagon secretion by pancreatic beta cells, are the two major pathophysiologic characteristics. The majority of type 2 diabetics will therefore require insulin in the evolution of their disease, with weight gain and hypoglycaemia as side effects. GLP-1 analogs are effective therapeutic alternatives due to their actions on glucagon and insulin secretion, on satiety and gastric emptying. For patients inadequately controlled with conventional antidiabetics, GLP-1 analogs, introduced as an alternative or in combination with insulin, can prevent or reduce the side effects associated with insulin. Indeed, the risk of hypoglycaemia is reduced and the vicious circle of weight gain secondary to insulin/need to increase insulin doses is limited.

  • Diabetes Mellitus, Type 2/drug therapy/etiology
  • Drug Therapy, Combination
  • Glucagon-Like Peptide 1/analogs & derivatives
  • Humans
  • Hypoglycemic Agents/administration & dosage
  • Incretins/administration & dosage
  • Insulin/administration & dosage
  • Molecular Targeted Therapy
Citation (ISO format)
DE KALBERMATTEN, Bénédicte Anne et al. Traitement combiné d’insuline et d’analogue du GLP-1 : qu’en attendre ? In: Revue médicale suisse, 2014, vol. 10, n° 433, p. 1235–1240.
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation11/23/2015 2:33:00 PM
First validation11/23/2015 2:33:00 PM
Update time03/14/2023 11:58:22 PM
Status update03/14/2023 11:58:21 PM
Last indexation08/29/2023 7:53:05 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack